Atorvastatin Given prior to Electrical Cardioversion Does Not Affect the Recurrence of Atrial Fibrillation in Patients with Persistent Atrial Fibrillation Who Are on Antiarrhythmic Therapy

Basit Öğe Kaydı
dc.contributor.authorDemir, Kenan
dc.contributor.authorCan, İlknur
dc.contributor.authorKoç, Fatih
dc.contributor.authorVatankulu, Mehmet Akif
dc.contributor.authorAyhan, Selim
dc.contributor.authorAkıllı, Hakan
dc.contributor.authorArıbaş, Alpay
dc.date.accessioned2020-03-26T18:13:50Z
dc.date.available2020-03-26T18:13:50Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective: In this study, our aim was to evaluate the effect of a higher dose of atorvastatin on the recurrence rate of atrial fibrillation (AF) after electrical cardioversion (EC) in addition to antiarrhythmic therapy. Subjects and Methods: 48 patients with persistent AF were included in this study. The patients were randomized to an atorvastatin 40-mg treatment group and a control group. Atorvastatin was started 3 weeks before EC and was continued for 2 months after EC. EC was performed using biphasic shocks after 3 weeks of treatment with the orally administered anticoagulant warfarin. Lipid and inflammatory parameters (high-sensitivity C-reactive protein, white blood cell count and fibrinogen level) were evaluated at the baseline and before EC. The endpoint of this study was electrocardiographically confirmed recurrence of AF of >10 min. Results: There were no significant differences in baseline characteristics and lipid and inflammatory marker levels between the treatment and control groups. Total cholesterol and low-density lipoprotein levels were significantly decreased in patients taking atorvastatin for 2 months compared with baseline values (174 +/- 31 vs. 129 +/- 25 mg/dl, p = 0.001, and 112 +/- 23 vs. 62 +/- 20 mg/dl, p = 0.001, respectively), while no significant change occurred in control patients (168 +/- 26 vs. 182 +/- 29 mg/dl, p = 0.07, and 99 +/- 18 vs. 108 +/- 26 mg/dl, p = 0.1, respectively). At the end of the 2-month follow-up period, 9 patients (20.5%) experienced AF recurrence, and there was no significant difference in AF recurrence rate between the treatment and control groups (26 vs. 13%; p = 0.2). Conclusion: Atorvastatin therapy prior to EC does not prevent the recurrence of arrhythmia in patients with persistent AF who are receiving antiarrhythmic therapy. Copyright (C) 2011 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000327674en_US
dc.identifier.endpage469en_US
dc.identifier.issn1011-7571en_US
dc.identifier.issn1423-0151en_US
dc.identifier.issue5en_US
dc.identifier.pmid21757938en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage464en_US
dc.identifier.urihttps://dx.doi.org/10.1159/000327674
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26177
dc.identifier.volume20en_US
dc.identifier.wosWOS:000292694700012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKARGERen_US
dc.relation.ispartofMEDICAL PRINCIPLES AND PRACTICEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAtorvastatinen_US
dc.subjectAtrial fibrillationen_US
dc.subjectElectrical cardioversionen_US
dc.titleAtorvastatin Given prior to Electrical Cardioversion Does Not Affect the Recurrence of Atrial Fibrillation in Patients with Persistent Atrial Fibrillation Who Are on Antiarrhythmic Therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu